About Strategia

Medical Advisory Board

Medical Advisory Board (Oncology)

The Strategia Therapeutics Medical Advisory Board is comprised of recognized experts in the oncology and hematology fields from leading academic facilities and research institutions.

All these individuals have devoted their time and medical expertise to improving the lives of people afflicted with cancer and hematologic malignancies. The role of the Strategia Medical Advisory Board is to provide strategic medical advice and counsel, as requested by the Strategia board of directors and senior management team. This advice will support the mission of Strategia Therapeutics: to help patients in need by accelerating the research and development of high quality, clinically viable drugs for truly unmet needs. Strategia seeks out new therapies that have the highest clinical promise and strive to make those drugs accessible to patients and caregivers in an expedient and affordable way. Together, Strategia and the Medical Advisory Board believe that we can change the future of the pharmaceutical industry with a new model for effective drug research and development for patients and their providers.

Daniel D. Von Hoff, MD, FACP

Daniel D. Von Hoff, MD, FACP

Daniel D. Von Hoff, M.D., F.A.C.P. is currently Physician in Chief, Distinguished Professor and Director of Clinical Translational Research Division at TGen (Translational Genomics Research Institute) in Phoenix, Arizona. He is also Chief Scientific Officer for US Oncology Research and for Scottsdale Healthcare’s Clinical Research Institute and Chief Development Officer for TD2, LLC. He holds an appointment as Professor of Medicine, Mayo Clinic, Scottsdale, AZ. Dr. Von Hoff’s major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including:  mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib and others.  At present, he and his colleagues are concentrating on the development of molecularly targeted therapies particularly for patients with advanced pancreatic cancer. Dr. Von Hoff has published more than 620 papers, 137 book chapters and over 1050 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology for his outstanding contributions to cancer research leading to significant improvement in patient care. Dr. Von Hoff was appointed to President Bush’s National Cancer Advisory Board in 2004-2010. Dr. Von Hoff is the past President of the American Association for Cancer Research (the world’s largest cancer research organization), a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme after Ilex had 2 agents, alemtuzumab and clofarabine approved by the FDA for patients with leukemia). Dr. Von Hoff is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics. He is a co-founder of the AACR/ASCO Methods in Clinical Cancer Research Workshop. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows.

Back to Top

Alan F. List, MD

Alan F. List, MD

Dr. Alan List is the President and Chief Executive Officer of Moffitt Cancer Center in Tampa, FL. Dr. List is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the U.S. Food and Drug Administration and approval for the treatment of patients with MDS and multiple myeloma. This work transformed the natural history of MDS from a premalignant condition that progressed to malignancy requiring aggressive treatment to a condition managed in the outpatient setting with oral agents. Prior to his current position, Dr. List served as Executive Vice President and Physician-in-Chief, the Vice Deputy Physician-in-Chief, and the Chief of the Malignant Hematology Division at Moffitt, where he holds the Morsani Endowed Chair. Before coming to Moffitt in 2003, Dr. List was a Professor of Medicine at the University of Arizona, Tucson, where he also served concurrently as the Director of the Leukemia and Blood and Marrow Transplant Program and Director of the Division of Translational/Clinical Research Program. After earning a medical degree in 1980 from the University of Pennsylvania, Philadelphia, Dr. List completed an internship and residency in internal medicine at the Good Samaritan Medical Center in Phoenix, Arizona. He then completed fellowships in hematology and medical oncology at Vanderbilt University Medical Center in Nashville, Tennessee. Dr. List receives peer-reviewed NIH support for his work and publishes extensively in the areas of MDS and acute leukemia. He lectures nationally and internationally and has received several awards in recognition of his seminal contributions such as induction into The Joshua Lederberg Society; the Emil J. Freireich Award for Clinical Research, M.D. Anderson (2006); the J.P. McCarthy International Prize for Advancing the Body of Scientific Knowledge in Myelodysplastic Syndrome (2004); and the General Motors Cancer Research Foundation Merit Award (1991). He is the author of more than 300 peer-reviewed articles and the Clinician’s Manual on Myelodysplastic Syndromes (2008). He serves as a member of the Myelodysplastic Syndrome Foundation Board of Directors. He also is an active member of the American Society of Clinical Oncology; American Society of Hematology; American Association for Cancer Research; International Society for Experimental Hematology; J.P. McCarthy Foundation Medical Advisory Committee; and the Southwestern Oncology Group.

Back to Top

Alex A. Adjei, MD, PHD, FACP

Alex A. Adjei, MD, PHD, FACP

Alex A. Adjei is Professor of Oncology and Chair of the Department of Medicine as well as Senior Vice-President for Clinical Research at the Roswell Park Cancer Institute (RPCI) in Buffalo, NY, USA. In addition, he holds the Katherine Anne Gioia Chair in Cancer Medicine at RPCI, and is Professor of Medicine and an Academic Scholar in Medicine at the State University of New York in Buffalo.  Dr Adjei has served on a number of US National Cancer Institute Committees. He was Lung Cancer Committee Chair and Vice-Chair of the North Central Cancer Treatment Group. He is currently co-Chair of the Thoracic Malignancies Steering Committee, and vice-chair of the Lung Cancer Translational Science Committee. He is the Editor-in-Chief of the Journal of Thoracic Oncology, and a member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC). Dr Adjei’s research is focused on pharmacogenetics, experimental therapeutics and clinical drug development. He has been a Principal Investigator of over 60 phase I trials and 20 phase II trials. He has served on advisory boards of virtually all the large pharmaceutical companies involved in oncology drug development as well as over 20 small biotechnology companies. He received the first ASCO Drug Development Research Professorship in 2012 in recognition of his mentorship and his work in cancer drug development. He has authored 227 publications dealing primarily with preclinical pharmacology and phase I trials as well as novel therapeutics/phase II trials of lung cancer.

Back to Top